ArticleFuture oncology (London, England)2026
Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.
Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02319837 (A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fourth episode in this podcast series features a discussion between the two principal investigators from the phase III EMBARK trial (NCT02319837). EMBARK showed that in patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide (enzalutamide combination) and enzalutamide monotherapy significantly improved metastasis-free survival compared with leuprolide alone. Furthermore, overall survival was significantly longer with enzalutamide combination compared with leuprolide alone. No new safety signals were observed, and health-related quality of life was maintained with enzalutamide combination and monotherapy (as determined by patient-reported outcomes). In this episode, the speakers discuss some of the results from EMBARK in more detail and provide their expert opinion on what the findings mean for clinical practice in the real world. They also answer some of the frequently asked questions that they receive about the study from people around the world, including discussion of whether the results apply regardless of primary therapy, if intermittent therapy is a possibility, and how the findings from EMBARK should be applied with respect to the availability of different imaging technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.